Get the Stockscreener App
1.43
0.69%
-0.01
After Hours:
1.42
-0.01
-0.70%
In 8 Bio Inc stock is traded at $1.43, with a volume of 11,081.
It is down -0.69% in the last 24 hours and down -10.63% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.44
Open:
$1.4658
24h Volume:
11,081
Relative Volume:
0.16
Market Cap:
$13.71M
Revenue:
-
Net Income/Loss:
$-18.98M
P/E Ratio:
-0.5011
EPS:
-2.8535
Net Cash Flow:
$-14.55M
1W Performance:
-1.38%
1M Performance:
-10.63%
6M Performance:
-14.88%
1Y Performance:
-39.92%
1-Day Range:
$1.41
$1.4658
1-Week Range:
$1.322
$1.4999
52-Week Range:
$1.17
$2.73
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.43 | 13.81M | 0 | -18.98M | -14.55M | -2.8535 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Korro Bio (NASDAQ: KRRO) investors back directors, pay and auditor - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
TELA Bio (NASDAQ: TELA) OKs 3.5M-share incentive plan boost - Stock Titan
Climb Bio (CLYM) details early budoprutug Phase 1b/2a ITP results and risks - Stock Titan
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
[8-K] Bio Green Med Solution, Inc. Reports Material Event - Stock Titan
Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments - Stock Titan
Climb Bio (CLYM) director receives stock options on 40,000 common shares - Stock Titan
Climb Bio (NASDAQ: CLYM) expands equity plan evergreen to cover pre-funded warrants - Stock Titan
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform - Business Wire
Gossamer Bio, Inc. 8-K Filing June 2026: Annual Meeting Results and Company Information - Minichart
Climb Bio, Inc. Files Form 8-K with SEC – Corporate Information, Stock Details, and Emerging Growth Status - Minichart
Climb Bio (NASDAQ: CLYM) advances CLYM116 toward Phase 2 IgAN trial - Stock Titan
Gossamer Bio (NASDAQ: GOSS) swaps $181M converts for new debt, equity and warrants - Stock Titan
Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay - Stock Titan
Valion Bio (NASDAQ: VBIO) investors approve major equity plan boost and share issuances - Stock Titan
Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan
New MRI biomarker backs INmune Bio (NASDAQ: INMB) Alzheimer’s drug - Stock Titan
Gossamer Bio (NASDAQ: GOSS) extends early tender deadline in major convertible note exchange - Stock Titan
Nuvation Bio Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart
Nuvation Bio (NUVB) shareholders elect directors, ratify KPMG and approve pay - Stock Titan
Passage Bio (NASDAQ: PASG) ends Gemma deal, pays $2.3M to exit lease - Stock Titan
Q32 Bio (NASDAQ: QTTB) prices $55M stock and pre-funded warrant sale - Stock Titan
Bio-Path (OTC: BPTH) unveils crypto treasury plan and $57.9M judgment tie - Stock Titan
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
VBIO SEC FilingsValion Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Exclusive Tokyo BCG supply deal expands ImmunityBio (NASDAQ: IBRX) options - Stock Titan
Debt exchange and FDA path shape Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Pharma-Bio Serv, Inc. Files Form 8-K Disclosing Submission of Matters to a Vote of Security Holders – May 2026 - Minichart
KALA BIO (KALA) files 13G/A: Baker Bros. reports 2,312 shares post-split - Stock Titan
Annovis Bio (NYSE: ANVS) ramps R&D as Phase 3 Alzheimer’s trial advances - Stock Titan
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
Instil Bio, Inc. Reports First Quarter 2026 Financial Results – 8-K Filing Details and Key Highlights - Minichart
[SCHEDULE 13G/A] Adicet Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027 - Stock Titan
Gossamer Bio, Inc.Common Stock (NQ: GOSS - FinancialContent
Valion Bio (VBIO) widens Q1 2026 loss as it builds TLR5 and CDMO platform - Stock Titan
INmune Bio (NASDAQ: INMB) wins FDA Fast Track status for XPro in early Alzheimer’s disease - Stock Titan
IPF Phase 2a results and cash runway update for GRI Bio (NASDAQ: GRI) - Stock Titan
Cabaletta Bio (NASDAQ: CABA) details Q1 loss and $150M financing - Stock Titan
Cabaletta Bio (NASDAQ: CABA) unveils new rese-cel autoimmune and PC-free data - Stock Titan
Adicet Bio (Nasdaq: ACET) trims Q1 loss and details prula-cel, ADI-212 plans - Stock Titan
Palisade Bio (NASDAQ: PALI) boosts R&D spend to advance PALI-2108 - Stock Titan
TELA Bio (NASDAQ: TELA) Q1 2026 revenue rises 3% to $19.1M - Stock Titan
TELA Bio rolls out fully resorbable hernia repair after $19M Q1 - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):